CLOV Quote, Financials, Valuation and Earnings

Centene has a net margin of -0.28% compared to Clover Health Investments's net margin of 2.81%. Clover Health Investments's return on equity of -7.67% beat Centene's return on equity of 12.65%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 55.22%. On the other hand Centene has an analysts' consensus of $54.74 which suggests that it could grow by 79.99%. Given that Centene has higher upside potential than Clover Health Investments, analysts believe Centene is more attractive than Clover Health Investments.

Clover Health Investments has a beta of 1.861, which suggesting that the stock is 86.075% more volatile than S&P 500. In comparison Centene has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.078%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are smaller than Centene quarterly revenues of $46.6B. Clover Health Investments's net income of -$1.3M is lower than Centene's net income of $1.3B. Notably, Clover Health Investments's price-to-earnings ratio is -- while Centene's PE ratio is 4.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.00x versus 0.09x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth has a net margin of -0.28% compared to Clover Health Investments's net margin of -5.44%. Clover Health Investments's return on equity of -7.67% beat NeueHealth's return on equity of -3241.93%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 55.22%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 2.04%. Given that Clover Health Investments has higher upside potential than NeueHealth, analysts believe Clover Health Investments is more attractive than NeueHealth.

Clover Health Investments has a beta of 1.861, which suggesting that the stock is 86.075% more volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are larger than NeueHealth quarterly revenues of $215.8M. Clover Health Investments's net income of -$1.3M is higher than NeueHealth's net income of -$11.7M. Notably, Clover Health Investments's price-to-earnings ratio is -- while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.00x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -0.28% compared to Clover Health Investments's net margin of 9.04%. Clover Health Investments's return on equity of -7.67% beat Oscar Health's return on equity of 10.83%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 55.22%. On the other hand Oscar Health has an analysts' consensus of $14.99 which suggests that it could fall by -2.32%. Given that Clover Health Investments has higher upside potential than Oscar Health, analysts believe Clover Health Investments is more attractive than Oscar Health.

Clover Health Investments has a beta of 1.861, which suggesting that the stock is 86.075% more volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are smaller than Oscar Health quarterly revenues of $3B. Clover Health Investments's net income of -$1.3M is lower than Oscar Health's net income of $275.3M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Oscar Health's PE ratio is 54.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.00x versus 0.42x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -0.28% compared to Clover Health Investments's net margin of 4.65%. Clover Health Investments's return on equity of -7.67% beat Progyny's return on equity of 11.16%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 55.22%. On the other hand Progyny has an analysts' consensus of $26.25 which suggests that it could grow by 14.03%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Clover Health Investments has a beta of 1.861, which suggesting that the stock is 86.075% more volatile than S&P 500. In comparison Progyny has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.703%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are larger than Progyny quarterly revenues of $324M. Clover Health Investments's net income of -$1.3M is lower than Progyny's net income of $15.1M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Progyny's PE ratio is 40.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.00x versus 1.78x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.